Clinical use of serum c-erbB-2 in patients with ovarian masses

Gynecologic and Obstetric Investigation

Volumn 48, Issue 2, 1999, Pages 133-137

  Cheung, T H ^a   Wong, Y F ^b   Chung, T K H ^b   Maimonis, P ^c   Chang, A M Z ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c Chiron Diagnostics   (United States)

Author keywords

C erbB 2 ECD; CA 125; Diagnostic utility

Indexed keywords

CA 125 ANTIGEN; GENE PRODUCT;

ADULT; ARTICLE; BENIGN TUMOR; BLOOD LEVEL; BORDERLINE STATE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ENZYME IMMUNOASSAY; FEMALE; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE C ERB; OVARY TUMOR; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032809321     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000010155     Document Type: Article

References (22)

1. Schubert D, Heinemann S, Carlisle W, Tarikas H, Kimes B, Patrick J, Steinbach JH, Culp W, Brandt BL: Clonal cell lines from the rat central nervous system. Nature 1974;249:224-227.
2. Fukushige S, Matsubara K, Yoshida M, Sasaki M, Suzuki T, Semba K, Toyoshima K: Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 1986;6:955-958.
3. King CR, Draus MH, Aaronson SA: Amplification of a novel c-erbB-related gene in a human mammary carcinoma. Science 1985;229:974-976.
4. Langton BC, Crenshaw MC, Chao LA, Stuart SG, Akita RW: An antigen immunologically related to external domain of gp185 is shed from nude mouse tumours overexpressing the c-erbB-2 (HER-2/neu). Cancer Res 1991;51: 2593-2598.
5. Volas GH, Leitzel K, Teramoto Y, Grossberg H, Demers L, Lipton A: Serial serum c-erbB-2 levels in patients with breast carcinoma. Cancer 1996;78:267-272.
6. Fehm T, Maimonis P, Weitz S, Teramoto Y, Katalinic A, Jager W: Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 1997;43:87-95.
7. Molina R, Jo J, Filella X, Bruix J, Castells A, Hague M, Ballesta AM: Serum levels of c-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. Tumour Biol 1997;18: 188-196.
8. Meden H, Marx D, Schauer A, Wuttke W, Kuhn W: Prognostic significance of p105 (c-erbB-2 HER2/neu) serum levels in patients with ovarian cancer. Anticancer Res 1997;17: 757-760.
9. Creaseman WT: Announcement, FIGO stages 1988 Revisions. Gynecol Oncol 1989;35:125-127.
10. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristics curve: A nonparametric approach. Biometrics 1988; 44:837-845.
11. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
12. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullnch A, Press MF: Studies of the HER-2 neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
13. Berchuck A, Kamel A, Kerns WB, Olt G, Kinney R, Soper IT, Dodge DL, Clarke-Pearson DL, Marks P, McKenzie S, Yin S, Bast RC Jr: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-4091.
14. Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz CP: HER-2/neu expression: A major prognostic factor in endometrial cancer. Gynecol Oncol 1992;47:179-185.
15. Kerin JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MI, Torney L, Robinson RA: p185 neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990;50:5184-5191.
16. Kraus MH, Popescu NC, Amsbaugh SC, King CR: Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 1987;6:605-610.
17. Weber W, Gill GN, Spiess J: Production of an epidermal growth factor receptor-related protein. Science 1984;224:294-297.
18. Langton BC, Crenshaw MC, Chao LA, Stuart SG, Akita RW, Jackson JE: An antigen immunologically related to the external domain of gp 185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER2/neu) oncogene. Cancer Res 1991;51:2593-2598.
19. Kacinski BM, Mayer AG, King BL, Carter D, Chambers SK: NEU protein overexpression in benign, borderline, and malignant ovarian neoplasm. Gynecol Oncol 1992;44:245-253.
20. Seidman JD, Frisman DM, Norris HJ: Expression of the HER-2/neu proto-oncogene in serous ovarian neoplasm. Cancer 1992;70:2857-2860.
21. Eltabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR: p53 and HER-2/neu overexpression in ovarian borderline tumours. Gynecol Oncol 1997;65:218-224.
22. Tholander B, Taube A, Lindgren A, Sjoberg O, Stendahl U, Kiviranta A, Hallman K, Holm L, Weiner E, Tamsen L: Pretreatment serum concentrations of CA 125, carcinoembryonic antigen, tissue polypeptide antigen and placental alkaline phosphatase in patients with ovarian carcinoma, borderline tumors or benign adnexal masses, relevance to differential diagnosis. Gynecol Oncol 1990;39:16-25.